161 related articles for article (PubMed ID: 34076868)
1. The Effect of Luteinising Hormone Suppression in In Vitro Fertilisation Antagonist Cycles.
Goh JP; Lee JCS; Chan JKY; Allen JC; Ng XW; Nadarajah S; Phoon JWL; Liu S
Reprod Sci; 2021 Nov; 28(11):3164-3170. PubMed ID: 34076868
[TBL] [Abstract][Full Text] [Related]
2. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
Vuong TN; Phung HT; Ho MT
Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
[TBL] [Abstract][Full Text] [Related]
3. Profound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF.
Kolibianakis EM; Zikopoulos K; Schiettecatte J; Smitz J; Tournaye H; Camus M; Van Steirteghem AC; Devroey P
Hum Reprod; 2004 Nov; 19(11):2490-6. PubMed ID: 15319383
[TBL] [Abstract][Full Text] [Related]
4. Dynamics of the development of multiple follicles during ovarian stimulation for in vitro fertilization using recombinant follicle-stimulating hormone (Puregon) and various doses of the gonadotropin-releasing hormone antagonist ganirelix (Orgalutran/Antagon).
de Jong D; Macklon NS; Eijkemans MJ; Mannaerts BM; Coelingh Bennink HJ; Fauser BC;
Fertil Steril; 2001 Apr; 75(4):688-93. PubMed ID: 11287020
[TBL] [Abstract][Full Text] [Related]
5. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study.
König TE; van der Houwen LE; Overbeek A; Hendriks ML; Beutler-Beemsterboer SN; Kuchenbecker WK; Renckens CN; Bernardus RE; Schats R; Homburg R; Hompes PG; Lambalk CB
Hum Reprod; 2013 Oct; 28(10):2804-12. PubMed ID: 23838159
[TBL] [Abstract][Full Text] [Related]
6. Conventional GnRH antagonist protocols versus long GnRH agonist protocol in IVF/ICSI cycles of polycystic ovary syndrome women: a systematic review and meta-analysis.
Kadoura S; Alhalabi M; Nattouf AH
Sci Rep; 2022 Mar; 12(1):4456. PubMed ID: 35292717
[TBL] [Abstract][Full Text] [Related]
7. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication.
Itskovitz-Eldor J; Kol S; Mannaerts B
Hum Reprod; 2000 Sep; 15(9):1965-8. PubMed ID: 10966996
[TBL] [Abstract][Full Text] [Related]
8. IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre-treatment before GnRH antagonist protocol and standard long GnRH agonist protocol: a prospective and randomized study.
Ye H; Huang GN; Zeng PH; Pei L
J Assist Reprod Genet; 2009 Mar; 26(2-3):105-11. PubMed ID: 19225876
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy of the gonadotropin-releasing hormone antagonist, ganirelix, in Korean women undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer with recombinant follicle-stimulating hormone.
Moon SY; Ku SY; Kim SM; Jee BC; Suh CS; Choi YM; Kim JG; Kim SH
J Obstet Gynaecol Res; 2005 Jun; 31(3):227-35. PubMed ID: 15916659
[TBL] [Abstract][Full Text] [Related]
10. LH on GnRH-ant day to basal LH affects the IVF/ICSI outcome of PCOS women undergoing GnRH-antagonist protocol.
Wei Y; Luan T; Shen J; Zhang J; Zhang J; Su Y; Ling X; Li X; Zhao C
Int J Gynaecol Obstet; 2024 Feb; 164(2):624-632. PubMed ID: 37724009
[TBL] [Abstract][Full Text] [Related]
11. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol.
Griesinger G; Schultze-Mosgau A; Dafopoulos K; Schroeder A; Schroer A; von Otte S; Hornung D; Diedrich K; Felberbaum R
Hum Reprod; 2005 May; 20(5):1200-6. PubMed ID: 15665010
[TBL] [Abstract][Full Text] [Related]
12. [Clinical application of gonadotropin-releasing hormone antagonist in Chinese women undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer].
Chen SL; Yin MN; Sun L; Li H; Chen X; Song HD; He JX; Zhu L; Xing FQ
Nan Fang Yi Ke Da Xue Xue Bao; 2007 May; 27(5):588-90. PubMed ID: 17545062
[TBL] [Abstract][Full Text] [Related]
13. The decrease of serum luteinizing hormone level by a gonadotropin-releasing hormone antagonist following the mild IVF stimulation protocol for IVF and its clinical outcome.
Yanaihara A; Yorimitsu T; Motoyama H; Ohara M; Kawamura T
J Assist Reprod Genet; 2008 Apr; 25(4):115-8. PubMed ID: 18368475
[TBL] [Abstract][Full Text] [Related]
14. Effect of gonadotrophin-releasing hormone (GnRH) antagonist during the LH surge in normal women and during controlled ovarian hyperstimulation.
Christin-Maitre S; Olivennes F; Dubourdieu S; Chabbert-Buffet N; Charbonnel B; Frydman R; Bouchard P
Clin Endocrinol (Oxf); 2000 Jun; 52(6):721-6. PubMed ID: 10848876
[TBL] [Abstract][Full Text] [Related]
15. In-vitro maturation of oocytes vs in-vitro fertilization with a gonadotropin-releasing hormone antagonist for women with polycystic ovarian syndrome: can superiority be defined?
Shavit T; Ellenbogen A; Michaeli M; Kartchovsky E; Ruzov O; Shalom-Paz E
Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():46-50. PubMed ID: 24965979
[TBL] [Abstract][Full Text] [Related]
16. Progestin primed ovarian stimulation using corifollitropin alfa in PCOS women effectively prevents LH surge and reduces injection burden compared to GnRH antagonist protocol.
Huang TC; Huang MZ; Seow KM; Yang IJ; Pan SP; Chen MJ; Hwang JL; Chen SU
Sci Rep; 2021 Nov; 11(1):22732. PubMed ID: 34815477
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of a GnRH Agonist Trigger Following a GnRH Antagonist or Flexible Progestin-Primed Ovarian Stimulation Cycle.
Kalafat E; Turkgeldi E; Yıldız S; Dizdar M; Keles I; Ata B
Front Endocrinol (Lausanne); 2022; 13():837880. PubMed ID: 35663329
[TBL] [Abstract][Full Text] [Related]
18. [Effects of cetrorelix versus ganirelix in gonadotropin-releasing hormone antagonist cycles for preventing premature luteinizing hormone surges and on clinical outcomes of IVF-ET cycles].
Zhang J; Zhou X; Chen Y; Zhang Q; Li Y; Zhe J; Chen X; Chen S
Nan Fang Yi Ke Da Xue Xue Bao; 2019 Oct; 39(10):1207-1212. PubMed ID: 31801718
[TBL] [Abstract][Full Text] [Related]
19. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
Propst AM; Bates GW; Robinson RD; Arthur NJ; Martin JE; Neal GS
Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156
[TBL] [Abstract][Full Text] [Related]
20. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
